AstraZeneca Plc increased its revenue by 15% in the first quarter, enabling it to spend more on research and development as well as the manufacture of a Covid-19 vaccine developed with the University of Oxford. The company also advanced its proposed $39 billion acquisition of Alexion Pharmaceuticals Inc, a US specialty pharmaceutical company. The transaction is expected to close in the third quarter.
